As chronic hepatitis B (CHB) becomes more treatable, there are growing numbers of older infected patients. The authors were interested in the choice of antiviral treatment (AVT) in the presence of multiple comorbidities by studying a territory-wide CHB cohort in Hong Kong between 2000-2017. CHB patients were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong and their demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis, obtained according to their first appearance in four time periods: 2000-2004, 2005-2009, 2010-2013 and 2014-2017. In the final analysis, 135,395 CHB patients were included, with a mean age increases over time from 41 years in 2000-2004 to 46 years in 2005-2009, 51 years in 2010-2013 and 55 years in 2014-2017. There was a trend of increasing prevalence of several common comorbidities over these four periods: hypertension 25.5%, 23.8%, 27.2% and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1% and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9% and 22.2%; and malignancy 7.0%, 13.2%, 17.3% and 23.6%. Therefore CHB patients are getting older, with an increasing prevalence of common comorbidities that should be taken into account when choosing AVT.
Read more here